REMINDER: New subscribers who are ISPE members can avail of a 10% discount if they sign up by October 15, 2020.
With B.R.I.D.G.E. TO DATA you can:
- Search by keyword / criteria
- Compare results
- Save & export search results
- Create database collections
Email: info@cotahealthcare.com
If you cannot reach the database manager, please try completing the contact form at:
https://cotahealthcare.com/contact/
1. Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023 Apr 13:1-6.
2. Ou SI, Hong JL, Christopoulos P, Lin HM, Vincent S, Churchill EN, Soeda J, Kazdal D, Stenzinger A, Thomas M. Distribution and Detectability of EGFR Exon 20 Insertion Variants in NSCLC. J Thorac Oncol. 2023 Feb 3:S1556-0864(23)00095-3.
3. Minchom A, Viteri S, Bazhenova L, Gadgeel SM, Ou SI, Trigo J, Bauml JM, Backenroth D, Bhattacharya A, Li T, Mahadevia P, Girard N. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy. Lung Cancer. 2022 Jun;168:74-82.
4. Hamadani M, Liao L, Yang T, Chen L, Moskowitz C. Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):373-381.
5. Kushi LH, Lasiter L, Belli AJ, et al. Trends in immunotherapy use in patients with advanced non-small cell lung cancer (aNSCLC) patients: Analysis of real-world data. Journal of Clinical Oncology 2020;38:e19311-e.
6. Rivera DRR, Lasiter L, Christian J, et al. Overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) patients treated with frontline chemotherapy or immunotherapy by comorbidity: A real-world data (RWD) collaboration. Journal of Clinical Oncology 2020;38:e19270-e.
7. Mathura S, Fung VK, Dilwali K, Lakshmanan AS. Incorporating molecular markers in standard prognostic models for DLBCL patients using real-world data. Journal of Clinical Oncology 2020;38:e19251-e.
8. Mathura S, Lane D, Hansen E, et al. Disparities in clinical characteristics and treatment of multiple myeloma in African American patients. Journal of Clinical Oncology 2020;38:e19008-e.
9. Lane D, Norden AD, Belli AJ, Wang C-K. Assessing real-world clinical response in patients with multiple myeloma (MM): A survey of the literature. Journal of Clinical Oncology 2020;38:e19260-e.
10. Gutierrez ME, Price KS, Lanman RB, et al. Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. JCO Precision Oncology 2019:1-9.
We are offering a 10% discount for first time subscribers of our resource www.bridgetodata.org.
New users must sign up by October 15, 2020. Contact us for more information
There is a growing interest among epidemiologists to investigate genetic risk factors for disease, alongside other risk factors. We present a case study that demonstrates how B.R.I.D.G.E. TO DATA® (www.bridgetodata.org) supports gene-disease association studies by allowing searching for genetic databases, reviewing data elements, and comparing cohorts for pooling.
We may not have a booth at this year’s virtual meeting for ICPE, but you can always visit us at our website to request a demo, view a sample set, or communicate with our DGI Team.
The Flatiron Health database is a longitudinal and nationwide database comprised of de-identified patient-level structured and unstructured data from an EHR data source, curated via technology-enabled abstraction. It includes de-identified data from >280 cancer clinics representing more than 2.5 million U.S. cancer patients.
Keep a look out for our latest poster, Data Sources for Studying Genetic Factors of Chronic Obstructive Pulmonary Disease (COPD), to be presented at ICPE 2020 (Sep. 16-17, 2020).
